Prelude Capital Management’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Prelude Capital Management’s Portfolio EIDX Stock Details EIDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-25,622	Closed	-$3.37M	–	1949
2020 Q4	$3.37M	Buy	+25,622	New	+$2.26M	0.09%	170

Prelude Capital Management's EIDX Position: Q1 2021 in Review

Prelude Capital Management sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 25,622 shares — an estimated $3.37M sold.

Prelude Capital Management first reported a position in EIDX in Q4 2020 and held it in 1 quarter. The position peaked at $3.37M in Q4 2020. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

Prelude Capital Management reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Prelude Capital Management sold 25,622 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $3.37M.
Prelude Capital Management first reported a position in Eidos Therapeutics, Inc. Common Stock in Q4 2020 and held it in 1 quarter.
Prelude Capital Management's Eidos Therapeutics, Inc. Common Stock position peaked at $3.37M in Q4 2020.
0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Prelude Capital Management's 13F filing for Q1 2021, filed 17 May 2021.